Development of novel anti-uricosuric agents based on the genomic strategy.
Development of novel anti-uricosuric agents based on the genomic strategy.
批准号:
14207004
负责人:
ENDOU Hitoshi
金额:
$25.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Urate is the major inert end product of purine degradation in higher primates in contrast to most other mammals because of the genetic silencing of hepatic oxidative enzyme uricase. The kidney plays a dominant role in urate elimination ; it excretes 70% of the daily urate production. Therefore, it is important to understand renal urate handling mechanism because the underexcretion of urate has been implicated in the development of hyperuricemia that leads to gout. The urate transport systems exist in the proximal tubule but they are complicated because of their bidirectional transport and the species differences. Recently, we have identified the urate-anion exchanger URAT1 (SLC22A12) in the human kidney and found that defects in SLC22A12 lead to idiopathic renal hypouricemia. URAT1 is targeted by uricosuric and antiuricosuric agents that affect urate excretion. Molecular identification of urate transporting proteins will lead to the new drug development for hyperuricemia.We also found … More that defects in SLC22A12 lead to idiopathic renal hypouricaemia (MIM number, 220150) and patients with such defects show a high fractional urate excretion such as 95 ± 10 % (normally <10%). These results indicate that URAT1 regulates blood urate level and vice versa, that is, to control blood urate levels, the URAT1 transport function should be regulated. A newly found genetic alteration in SLC22A12 from a patient of an idiopathic renal hypouricaemia has prompted us to consider the importance of the URAT1 extreme intracellular C-terminal region for its function. A 5-bp deletion near the URAT1 C-terminal end (1639-1643del) causes frameshift and the seven amino acids in the terminal sequences have changed into eight different amino acids. The URAT1 transport activity of this mutation is low in the Xenopus oocyte expression system. Interestingly, the PDZ binding motif at the C-terminal end of URAT1, which is known to participate in protein-protein interaction, disappears by this amino acid sequence modification.In this study, we use the yeast two-hybrid approach to investigate the putative URAT1-associated proteins that modulate its transport function. We identify the multivalent PDZ domain-containing protein PDZK1 as an apparent partner of URAT1 in the human kidney. Moreover, we show a functional consequence of PDZK1/URAT1 interaction in transfected HEK293 cells, where URAT1 transport activities were increased by 1.4-fold by coexpression of PDZK1. We speculate that PDZK1 is a scaffolding protein that may be a physiological regulator of the function of URAT1. Less
期刊论文(111)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1097/01.asn.0000107560.80107.19
发表时间:
2004-02-01
期刊:
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
影响因子:
13.6
作者:
[Hosoyamada, M, Ichida, K, Endou, H]
通讯作者:
Endou, H
Takeda M, Norshio R, Onozato ML, Tojo A, Hasannejad H, Hang XL, Narikawa S, Endou H.: "Evidence for a role of human organic anion transporters in the muscular side effects of HMG-GoA reductase inhibitors."Eur.J.Pharmacol.. 483. 133-138 (2004)
Takeda M、Norshio R、Onozato ML、Tojo A、Hasannejad H、Hang XL、Narikawa S、Endou H.:“人类有机阴离子转运蛋白在 HMG-GoA 还原酶抑制剂肌肉副作用中作用的证据。”Eur。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Neprhrin and podocin expression aroung the onset of puromycin aminonucleoside nephrosis.
嘌呤霉素氨基核苷肾病发作时去氧肾上腺素和足多辛的表达。
DOI:
--
发表时间:
2005
期刊:
J.Pharmacol.Sci. 97
影响因子:
--
作者:
[Hosoyamada M, Yan K, Nishibori Y, Takiue Y, Kudo A, Kawkami H, Shibasaki T, Endou H]
通讯作者:
Endou H
シリーズ・バイオサイエンスの新世紀
系列:生物科学新世纪
DOI:
--
发表时间:
2002
期刊:
影响因子:
--
作者:
[Chairoungdua A, Kanai Y, Matsuo H, Inatomi J, Kim DK, Endou H, 宮崎 博喜, 安西 尚彦, 榎本 篤, 金井好克]
通讯作者:
金井好克
Koepsell H, Endou H.: "The SLC22 drug transporter family."Pflugers Arch.. 447. 666-676 (2004)
Koepsell H、Endou H.:“SLC22 药物转运蛋白家族”。Pflugers Arch.. 447. 666-676 (2004)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 77 条
Genetic Abnormality of Renal Proximal Tubule-Specific Transporters as Causes of Sudden Death Syndrome in South-Eastern Asia
-
批准号:13376004
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$17.64万
-
财政年份:2001
-
负责人:ENDOU Hitoshi
-
依托单位:
Identification of transporter genes regulating systemic kinetics of drugs and foreign compounds and their genetic polymorphism
-
批准号:12357016
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$27.62万
-
财政年份:2000
-
负责人:ENDOU Hitoshi
-
依托单位:
Molecular mechanisms of drug transport across cell membrane
-
批准号:11694310
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.78万
-
财政年份:1999
-
负责人:ENDOU Hitoshi
-
依托单位:
Molecular cloning and functional expression of kidney-specific organic anionic drug transporters
-
批准号:09470025
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.17万
-
财政年份:1997
-
负责人:ENDOU Hitoshi
-
依托单位:
Role of vanadium in endemic diseases in Northeast Thailand
-
批准号:07041167
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$5.25万
-
财政年份:1995
-
负责人:ENDOU Hitoshi
-
依托单位:
Establishment of immotalized cell lines from transgenic mouse nephron segments
-
批准号:04557122
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B)
-
资助金额:$11.14万
-
财政年份:1992
-
负责人:ENDOU Hitoshi
-
依托单位:
Endemic Primary Distal Renal Tubular Acidosis in Thailand
-
批准号:04041041
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$8.32万
-
财政年份:1992
-
负责人:ENDOU Hitoshi
-
依托单位:
Establishment of screening systems for evaluating drug actions in the kidney
-
批准号:01870111
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$7.87万
-
财政年份:1989
-
负责人:ENDOU Hitoshi
-
依托单位:
ULTRAMICRO METHODS FOR DETERMINING ENZYME ACTIVITIES AND SUBSTRATES USING COMBINED BIOLUMINESCENT ASSAY WITH ENZYMATIC CYCLING
-
批准号:62870009
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$4.29万
-
财政年份:1987
-
负责人:ENDOU Hitoshi
-
依托单位:
Intrarenal actions of atrial natriuretic peptides
-
批准号:61570094
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1986
-
负责人:ENDOU Hitoshi
-
依托单位:
海外基金